search
Back to results

Effectiveness of Sana Treatment in Post-Traumatic Stress Disorder (PTSD)

Primary Purpose

Post Traumatic Stress Disorder

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Sana Device
Sponsored by
Sana Health
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Post Traumatic Stress Disorder

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Having served, or are currently serving, in the US military with a VA CPRS record.
  • Willing to and capable of providing written electronic informed consent prior to the conduct of any study-related procedures.
  • Adults, of any sex or gender, 18 to 65 years of age.
  • Diagnosis of PTSD as determined by a Clinician Administered PTSD Scale for DSM-5 (CAPS-5) clinical interview or CAPS-5 severity ≥ 25.
  • Must be in good physical health based on self-report.
  • Any psychotropic drug therapy regimen must be stable (unchanging) for at least 4 weeks prior to enrollment and remain steady throughout the study.
  • Willing and able to comply with the study requirements, complete study assessments, and participate at scheduled times for the duration of the study.
  • Able to understand, speak, and read English sufficient for the completion of study assessments.
  • Provision of appropriate storage and charging for study equipment in a generally safe and dry condition.

Exclusion Criteria:

  • Pregnant, intending to become pregnant, or lactating females as self-reported.
  • History or presence of photo-sensitive epilepsy or other photo-sensitive conditions as self-reported.
  • History or presence of condition(s) that may affect balance, such as seizure disorders or vertigo as self-reported.
  • History or presence of severe and continuous tinnitus, at investigator discretion
  • Surgery or trauma requiring rehabilitation within the last 12 weeks as self-reported. Presence of cancer pain, acute pain following injury or other severe pain that would be anticipated to change during the course of the study, at discretion of the investigator.
  • Vision impairments that affect perception of light, color, or brightness in one or both eyes, and differences in visual perception between eyes, per patient self-report.
  • Deafness in one or both ears, perceived differences in hearing between ears, per patient self-report.
  • Current ear or eye infection, untreated allergies, or acute illness that may affect eyes or hearing (e.g., due to congestion), per patient self-report.
  • Presence of inflammation or broken skin around the eyes in the area of the mask, per patient self-report.
  • Presence of narcolepsy or untreated sleep apnea, per patient self-report. Note: presence of sleep apnea is permitted, so long as patients feel comfortable to use both apnea mask and Sana device in conjunction.
  • Participation in any other clinical study in which medication(s) are being delivered or have used an investigational drug or device within the last 30 days.
  • Any pending legal action that could prohibit participation or compliance in the study, per patient self-report.
  • Recent history of or current evidence of suicidal intent or active suicidal behavior based on patient self-report at investigator discretion.
  • Significant medical conditions or other circumstances which, in the opinion of the investigator, would preclude compliance with the protocol, adequate cooperation in the study or obtaining informed consent, or may prevent the patient from safely participating in study.
  • Employment by the investigator or the study site, with direct involvement in the proposed study or other studies under the direction of the investigator or study site, or a family member of an employee or of the investigator.
  • Use of drugs that can produce hallucinogenic effects (i.e., Ketamine or psilocybin mushrooms) within the past 4 weeks.

Sites / Locations

  • Ralph H. Johnson Veteran Affairs Medical Center/Lowcountry Center for Veterans ResearchRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

No Intervention

Arm Label

Sana plus Treatment as Usual

Treatment as Usual

Arm Description

Subjects will be loaned a Sana Device to use for 28 days and will also receive mental health care through the Ralph H. Johnson VA Medical Center.

Subjects will receive mental health care at the Ralph H. Johnson VA Medical Center or community-based outpatient clinic (CBOC).

Outcomes

Primary Outcome Measures

To examine the difference between Sana plus Treatment as Usual (Sana+TAU) and Treatment as Usual (TAU) on changes in PTSD symptoms as measured by the Clinician Administered PTSD Scale for DSM-5 (CAPS-5) after 28 days.
A 30-item structured interview that can be used to diagnosis and assess PTSD symptoms and severity.

Secondary Outcome Measures

To examine the difference between Sana+TAU and TAU on changes in PTSD symptoms as measured by the PTSD Checklist - 20-item scale for DSM-5 (PCL-5) after 28 days.
A 20-item self-reported measure that assesses the 20 DSM-5 symptoms of PTSD.
To examine the difference between Sana+TAU and TAU on anxiety symptoms as measured by the Generalized Anxiety Disorder 7-item scale (GAD-7) after 28 days.
The GAD-7 is a self-reported questionnaire for screening and measuring severity of generalized anxiety disorder.
To examine the difference between Sana+TAU and TAU on depression symptoms as measured by the Patient Health Questionnaire 9 (PHQ-9) after 28 days.
A self-reported questionnaire for screening and measuring severity of generalized anxiety disorder.
To examine the difference between Sana+TAU compared to TAU on perceived change in quality of life over TAU as measured by the Patient Global Impression of Change scale (PGIC) after 28 days.
A validated tool for screening, diagnosing, monitoring and measuring depression severity and scores each of the 9 Diagnostic and Statistical Manual of Mental Disorder, Fourth Edition (DSM-IV) related criteria.

Full Information

First Posted
April 1, 2022
Last Updated
May 23, 2023
Sponsor
Sana Health
Collaborators
Ralph H. Johnson VA Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT05319405
Brief Title
Effectiveness of Sana Treatment in Post-Traumatic Stress Disorder (PTSD)
Official Title
A Pilot Investigation of the Effectiveness of the Sana Device in Management of PTSD: A Blinded Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Recruiting
Study Start Date
April 19, 2023 (Actual)
Primary Completion Date
September 29, 2023 (Anticipated)
Study Completion Date
September 29, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sana Health
Collaborators
Ralph H. Johnson VA Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to assess the effectiveness of the Sana Device when added to Treatment as Usual in participants with a diagnosis of post-traumatic stress disorder (PTSD)
Detailed Description
This is a study designed to assess the effectiveness of the Sana Device when added to Treatment as Usual in participants with a diagnosis of post-traumatic stress disorder (PTSD) on severity of symptoms as measured by CAPS-5. We will use a 2-arm repeated measures randomized controlled design in which participants will be randomly assigned to either Sana plus Treatment as Usual (Sana+TAU) or Treatment as Usual (TAU).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Post Traumatic Stress Disorder

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Parallel 2-arm study in which participants will be randomly assigned to either Sana plus Treatment as Usual (Sana+TAU) or Treatment as Usual (TAU)
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Sana plus Treatment as Usual
Arm Type
Active Comparator
Arm Description
Subjects will be loaned a Sana Device to use for 28 days and will also receive mental health care through the Ralph H. Johnson VA Medical Center.
Arm Title
Treatment as Usual
Arm Type
No Intervention
Arm Description
Subjects will receive mental health care at the Ralph H. Johnson VA Medical Center or community-based outpatient clinic (CBOC).
Intervention Type
Device
Intervention Name(s)
Sana Device
Intervention Description
Externally worn mask that physically contacts the skin of the face. The Sana Device delivers Audio Visual Stimulation (AVS) in the form of coordinated pulses of light (through closed eyelids) and sound at various frequencies.
Primary Outcome Measure Information:
Title
To examine the difference between Sana plus Treatment as Usual (Sana+TAU) and Treatment as Usual (TAU) on changes in PTSD symptoms as measured by the Clinician Administered PTSD Scale for DSM-5 (CAPS-5) after 28 days.
Description
A 30-item structured interview that can be used to diagnosis and assess PTSD symptoms and severity.
Time Frame
Baseline and Day 28
Secondary Outcome Measure Information:
Title
To examine the difference between Sana+TAU and TAU on changes in PTSD symptoms as measured by the PTSD Checklist - 20-item scale for DSM-5 (PCL-5) after 28 days.
Description
A 20-item self-reported measure that assesses the 20 DSM-5 symptoms of PTSD.
Time Frame
Baseline, Days 14 and 28
Title
To examine the difference between Sana+TAU and TAU on anxiety symptoms as measured by the Generalized Anxiety Disorder 7-item scale (GAD-7) after 28 days.
Description
The GAD-7 is a self-reported questionnaire for screening and measuring severity of generalized anxiety disorder.
Time Frame
Baseline, Days 14 and 28
Title
To examine the difference between Sana+TAU and TAU on depression symptoms as measured by the Patient Health Questionnaire 9 (PHQ-9) after 28 days.
Description
A self-reported questionnaire for screening and measuring severity of generalized anxiety disorder.
Time Frame
Baseline, Days 14 and 28
Title
To examine the difference between Sana+TAU compared to TAU on perceived change in quality of life over TAU as measured by the Patient Global Impression of Change scale (PGIC) after 28 days.
Description
A validated tool for screening, diagnosing, monitoring and measuring depression severity and scores each of the 9 Diagnostic and Statistical Manual of Mental Disorder, Fourth Edition (DSM-IV) related criteria.
Time Frame
Baseline, Days 14 and 28

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Having served, or are currently serving, in the US military with a VA CPRS record. Willing to and capable of providing written electronic informed consent prior to the conduct of any study-related procedures. Adults, of any sex or gender, 18 to 65 years of age. Diagnosis of PTSD as determined by a Clinician Administered PTSD Scale for DSM-5 (CAPS-5) clinical interview or CAPS-5 severity ≥ 25. Must be in good physical health based on self-report. Any psychotropic drug therapy regimen must be stable (unchanging) for at least 4 weeks prior to enrollment and remain steady throughout the study. Willing and able to comply with the study requirements, complete study assessments, and participate at scheduled times for the duration of the study. Able to understand, speak, and read English sufficient for the completion of study assessments. Provision of appropriate storage and charging for study equipment in a generally safe and dry condition. Exclusion Criteria: Pregnant, intending to become pregnant, or lactating females as self-reported. History or presence of photo-sensitive epilepsy or other photo-sensitive conditions as self-reported. History or presence of condition(s) that may affect balance, such as seizure disorders or vertigo as self-reported. History or presence of severe and continuous tinnitus, at investigator discretion Surgery or trauma requiring rehabilitation within the last 12 weeks as self-reported. Presence of cancer pain, acute pain following injury or other severe pain that would be anticipated to change during the course of the study, at discretion of the investigator. Vision impairments that affect perception of light, color, or brightness in one or both eyes, and differences in visual perception between eyes, per patient self-report. Deafness in one or both ears, perceived differences in hearing between ears, per patient self-report. Current ear or eye infection, untreated allergies, or acute illness that may affect eyes or hearing (e.g., due to congestion), per patient self-report. Presence of inflammation or broken skin around the eyes in the area of the mask, per patient self-report. Presence of narcolepsy or untreated sleep apnea, per patient self-report. Note: presence of sleep apnea is permitted, so long as patients feel comfortable to use both apnea mask and Sana device in conjunction. Participation in any other clinical study in which medication(s) are being delivered or have used an investigational drug or device within the last 30 days. Any pending legal action that could prohibit participation or compliance in the study, per patient self-report. Recent history of or current evidence of suicidal intent or active suicidal behavior based on patient self-report at investigator discretion. Significant medical conditions or other circumstances which, in the opinion of the investigator, would preclude compliance with the protocol, adequate cooperation in the study or obtaining informed consent, or may prevent the patient from safely participating in study. Employment by the investigator or the study site, with direct involvement in the proposed study or other studies under the direction of the investigator or study site, or a family member of an employee or of the investigator. Use of drugs that can produce hallucinogenic effects (i.e., Ketamine or psilocybin mushrooms) within the past 4 weeks.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mark Robberson, MBEE
Phone
602-448-7127
Email
mark.robberson@sana.io
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ronald Acierno, PhD
Organizational Affiliation
Ralph H. Johnson VA Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ralph H. Johnson Veteran Affairs Medical Center/Lowcountry Center for Veterans Research
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29401
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephanie Hart, MPH, CCRC
First Name & Middle Initial & Last Name & Degree
Ronald Acierno, PhD
First Name & Middle Initial & Last Name & Degree
Wendy Muzzy, MRA, MLIS

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Effectiveness of Sana Treatment in Post-Traumatic Stress Disorder (PTSD)

We'll reach out to this number within 24 hrs